Immuno-Oncology | Specialty

PD-1 Immunotherapy Combos May Be Next Step in Hodgkin Lymphoma Therapy

October 29th 2015

The prospect of combining PD-1 inhibitors with existing therapies, particularly brentuximab vedotin, is emerging as the most exciting new development in advancing the treatment of patients with Hodgkin lymphoma, raising the possibility of improving the cure rates in a disease where standard strategies have already produced notable results.

FDA Approves Adjuvant Ipilimumab in Melanoma

October 28th 2015

The FDA expanded the approval of ipilimumab (Yervoy) in melanoma to include adjuvant treatment of patients with stage III melanoma at high risk of recurrence following complete resection.

FDA Approves T-VEC for Advanced Melanoma

October 27th 2015

The FDA has approved talimogene laherparepvec for the treatment of patients with advanced melanoma.

Pembrolizumab Improves Survival Versus Docetaxel in PD-L1+ NSCLC

October 26th 2015

Pembrolizumab (Keytruda) extended overall survival versus docetaxel in the phase II/III KEYNOTE-010 trial.

Enhanced Immune Response Seen With Radiation/Ipilimumab Combo in Melanoma

October 24th 2015

Proinflammatory cytokines were elevated in patients with melanoma undergoing the combination treatment of radiation therapy and the systemic anti–CTLA-4 immunotherapy, ipilimumab.

Mayo Study Characterizes Pembrolizumab-Induced Thyroiditis

October 23rd 2015

Abnormal thyroid function tests were reported in up to 15% of patients treated with the PD-1 inhibitor pembrolizumab.

CHMP Recommends T-VEC Approval for Melanoma

October 23rd 2015

Talimogene laherparepvec has received a positive recommendation from the CHMP, which suggests that the treatment should gain European approval for patients with advanced melanoma.

Dr. Reidy Lagunes on the Potential of Immunotherapy in NETs

October 21st 2015

Diane Reidy Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential of immunotherapy agents in the treatment of patients with neuroendocrine carcinoma.

Dr. Kunz on Potential of Immunotherapy in Neuroendocrine Tumors

October 17th 2015

Pamela L. Kunz, MD, assistant professor of Medicine (Oncology), Stanford University School of Medicine, discusses the potential of immunotherapy in the treatment of patients with neuroendocrine tumors (NETs).

Nivolumab Investigator Discusses Expanded Approval, Compares With Pembrolizumab

October 16th 2015

Dr. Ben Creelan, discusses the impact of the expanded approval of nivolumab in NSCLC and how the drug compares with pembrolizumab.

TILs Emerge as Robust Biomarker, Shed Light on Immunotherapy Potential in TNBC

October 14th 2015

Sylvia Adams, MD, explains the potential of TILs, as well as other biomarkers, including PD-1/PD-L1, in TNBC and other breast cancer types.

Dr. Raffit Hassan on Avelumab in Unresectable Mesothelioma

October 12th 2015

Raffit Hassan, MD, Co-Chief Thoracic and Gastrointestinal Oncology Branch, Senior Investigator Head, Thoracic and Solid Tumor Immunotherapy Section at the Center for Cancer Research, National Cancer Institute, discusses a recent phase IB trial investigating avelumab in unresectable mesothelioma.

Combining TKIs and Immunotherapies in GIST

October 9th 2015

Emerging Therapies for Gastrointestinal Stromal Tumors

October 9th 2015

Therapeutic Options for Progressive GIST

October 9th 2015

Tyrosine Kinase Inhibition in Gastrointestinal Stromal Tumors

October 9th 2015

Multidisciplinary Treatment for GIST

October 9th 2015

Factors Impacting Neoadjuvant Treatment of GIST

October 9th 2015

Assessing Response to Imatinib in GIST

October 9th 2015

Adjuvant Imatinib for Gastrointestinal Stromal Tumor

October 9th 2015